Rituxan, Mabthera(rituximab)
Blitzima, MabThera, Riabni, Rituxan, Rixathon, Riximyo, Ruxience, Truxima (rituximab) is an antibody pharmaceutical. Rituximab was first approved as Rituxan on 1997-11-26. It is used to treat b-cell lymphoma, granulomatosis with polyangiitis, lymphoid leukemia, mantle-cell lymphoma, and microscopic polyangiitis amongst others in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia, microscopic polyangiitis, non-hodgkin lymphoma, pemphigus, and rheumatoid arthritis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Riabni, Rituxan, Ruxience, Truxima (discontinued: Rituxan)
CombinationsRituxan hycela
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| riabni | Biologic Licensing Application | 2025-09-12 |
| rituxan | Biologic Licensing Application | 2025-01-06 |
| rituxan hycela | Biologic Licensing Application | 2025-12-15 |
| ruxience | Biologic Licensing Application | 2026-04-08 |
| truxima | Biologic Licensing Application | 2025-06-18 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
rituximab, Rituxan, Genentech, Inc. | |||
| 2026-09-27 | Orphan excl. | ||
rituximab / hyaluronidase human, Rituxan Hycela, Genentech, Inc. | |||
| 2024-06-22 | Orphan excl. | ||
Patent Expiration
No data
Clinical
Clinical Trials
2763 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 8 | 3 | 2 | 1 | 14 |
| Lymphoma | D008223 | — | C85.9 | 4 | 10 | — | 1 | 1 | 12 |
| Proteinuria | D011507 | — | R80 | — | — | — | 1 | — | 1 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 6 | 1 | — | — | 7 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | 3 | — | 1 | 5 |
| Follicular lymphoma | D008224 | — | C82 | 1 | 4 | 1 | — | — | 5 |
| Leukemia | D007938 | — | C95 | 1 | 2 | 1 | — | — | 3 |
| Recurrence | D012008 | — | — | — | — | 2 | — | — | 2 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 1 | 2 | 1 | — | — | 2 |
| Lymphoid leukemia | D007945 | — | C91 | — | 1 | 1 | — | — | 2 |
| B-cell lymphoma | D016393 | — | — | — | — | 1 | — | — | 1 |
| Thrombocytopenic purpura | D011696 | — | — | — | 1 | 1 | — | — | 1 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | 3 | — | — | — | 3 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 3 | — | — | — | 3 |
| Kidney transplantation | D016030 | — | — | 1 | 1 | — | — | — | 1 |
| Churg-strauss syndrome | D015267 | EFO_0007208 | M30.1 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | 1 | — | — | — | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | 1 | — | — | — | 1 |
| Large-cell lymphoma immunoblastic | D016400 | — | — | 1 | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | 1 | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rituximab |
| INN | rituximab |
| Description | Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow injection into a vein.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies: chimeric, tumors as target |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >1L6X:A|IMMUNOGLOBULIN GAMMA-1 HEAVY CHAIN CONSTANT REGION
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
>1L6X:B|Minimized B-domain of Protein A Z34C
FNMQCQRRFYEALHDPNLNEEQRNAKIKSIRDDC |
Identifiers
| PDB | 1L6X, 2OSL, 4KAQ, 6VJA, 6Y90 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201576 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00073 |
| UNII ID | 4F4X42SYQ6 (ChemIDplus, GSRS) |
Target
Agency Approved
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Alternate
No data
Variants
No data
Financial
Estimated US medical usage
Rituximab
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Riabni, Rituxan, Rituxan hycela, Ruxience, Truxima
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
224,953 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use